Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | HPGDS | O60760 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958653 | 1.00 | USP30 (0.60) | USP30PDE4BHPGDSTP53MAPT | |
| SCHEMBL28834093 | 1.00 | USP30 (0.60) | USP30PDE4BHPGDSTP53MAPT | |
| SCHEMBL22945386 | 0.94 | USP30 (0.64) | USP30PDE4BHPGDSNR1H2RXRA | |
| SCHEMBL29386809 | 0.93 | GPR119 (0.55) | USP30HPGDSTP53MAPTGPR119 | |
| SCHEMBL12354143 | 0.93 | GPR119 (0.55) | USP30HPGDSTP53MAPTGPR119 | |
| SCHEMBL23951735 | 0.89 | TP53 (0.59) | USP30PDE4BHPGDSTP53MAPT | |
| SCHEMBL697513 | 0.89 | TP53 (0.59) | USP30PDE4BHPGDSTP53MAPT | |
| SCHEMBL1751432 | 0.89 | TP53 (0.59) | USP30PDE4BHPGDSTP53MAPT | |
| SCHEMBL12354139 | 0.86 | USP30 (0.55) | USP30HPGDSGPR119NR1H2RXRA | |
| SCHEMBL2556685 | 0.86 | PDE4B (0.56) | USP30PDE4BHPGDSTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | USP30 1231/4885PDE4B 224/4885HPGDS 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.